Feasibility of Anti-VEGF Agent Bevacizumab in Patients with Crohn's Disease

被引：15

作者：

Coriat, Romain ^{[1
,2
]}

Mir, Olivier ^{[1
]}

Leblanc, Sarah ^{[2
]}

Ropert, Stanislas ^{[1
]}

Brezault, Catherine ^{[2
]}

Chaussade, Stanislas ^{[2
]}

Goldwasser, Francois ^{[1
]}

机构：

[1] Paris Descartes Univ, Dept Med Oncol, Cochin Teaching Hosp, CERIA Ctr Res Angiogenesis Inhibitors, Paris, France

[2] Paris Descartes Univ, Gastroenterol Unit, Cochin Teaching Hosp, Paris, France

来源：

INFLAMMATORY BOWEL DISEASES | 2011年 / 17卷 / 07期

关键词：

GROWTH-FACTOR;

D O I：

10.1002/ibd.21545

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

引用

页码：1632 / 1632

页数：1

共 7 条

[1]

Ducreux M, 2010, INT J CANC

[2]

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

[3]

Platelet-derived growth factor-BB reflects clinical, inflammatory and angiogenic disease activity and oxidative stress in inflammatory bowel disease [J].

Krzystek-Korpacka, Malgorzata ;

Neubauer, Katarzyna ;

Matusiewicz, Malgorzata .

CLINICAL BIOCHEMISTRY, 2009, 42 (16-17) :1602-1609

[4]

Platelet-derived growth factor and its receptors are expressed in areas of both active inflammation and active fibrosis in inflammatory bowel disease [J].

Kumagai, S ;

Ohtani, H ;

Nagai, T ;

Funa, K ;

Hiwatashi, N ;

Shimosegawa, T ;

Nagura, H .

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 195 (01) :21-33

[5]

Loriot Y, 2008, ANN ONCOL, V19, DOI 10.1093/annonc/mdn566

[6]

CROHNS-DISEASE AND CANCER [J].

WEEDON, DD ;

SHORTER, RG ;

ILSTRUP, DM ;

HUIZENGA, KA ;

TAYLOR, WF .

NEW ENGLAND JOURNAL OF MEDICINE, 1973, 289 (21) :1099-1103

[7]

COLORECTAL-CANCER SCREENING [J].

WINAWER, SJ ;

SCHOTTENFELD, D ;

FLEHINGER, BJ .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (04) :243-253

← 1 →